October 7, 2020 6:50pm

Making the grade, is making enhancing value to your portfolio

Pre-open indication results: 5 HITs and 0 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +530.70 points (+1.91%), the S&P closed UP +58.50 points (+1.74 %) while the Nasdaq closed UP +209.99 points (+1.88%)

 

Henry’omics:

U.S. stocks rose sharply on Wednesday after President Donald Trump tweeted support for aid to airlines and other stimulus measures, stoking hope that a smaller aid package could be passed by lawmakers.

  • In a series of tweets Tuesday night, Trump urged Congress to approve airline payroll support, saying that money and aid for small business could be paid for with unused funds from the previous stimulus. Trump also pushed for another round of $1,200 stimulus checks for Americans. <CNBC>

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: rebound; second stimulus bill talks were off the table until Trump tweeted some aid is now possibly back on” … https://www.regmedinvestors.com/articles/11578

 

Pre-open indications: 5 HITs < Biostage (BSTG -$0.09), BUY - Pluristem (PSTI +$0.55), Sangamo Therapeutics (SGMO +$1.42); SELL into Strength - BioLife Solutions (BLFS -$0.09), Solid Biosciences (SLDB -$0.27) and 0 MISS

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Wednesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 28/5 and 2 flats, closing positive at 26/7 and 2 flats;
  • Tuesday opened positive at 17/15 and 2 flats, stayed positive at the mid-day at 21/13 and 1 flat, closing negative at 11/23 and 1 flat;
  • Monday opened positive at 31/3 and 1 flat, stayed positive at the mid-day at 33/1 and 1 flat, closing positive at 33/1 and 1 flat;

 

Key metrics:

  • Sector volume was the usual LOW with 8 of the 26-upside having higher than the 3-month average volume with the increased volume of 0 of 7-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 26-upside were +0.54% (CLBS) to +13.18% (NTLA) while the 9-downside ranges from -0.31% (BLFS) to -6.18% (SLDB);

 

Hammered in today’s market:

  • Solid Bioscience (SLDB), BioLife Solutions (BLFS), uniQure NV (QURE), MiMedx (OTC Pink sheets: MDXG), Mesoblast (MESO), Athersys (ATHX), Biostage (BSTG) to name 7 of the 7 declining of the 35 covered

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Ultragenyx (RARE), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Fate Therapeutics (FATE) to name 5 of the 26 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed up +2.26% and XBI closed up +3.20%
  • Tuesday, the IBB closed down -1.21% and XBI closed down -0.79%
  • Monday, the IBB closed up +4.26% and XBI closed up +4.94%

 

Wednesday’s (10 of 26) incliners:

  • CRISPR Therapeutics (CRSP +$9.96 after Tuesday’s +$0.97 and Monday’s +$7.08);
  • Ultragenyx (RARE +$5.31 after Tuesday’s -$0.36 and Monday’s +$4.85);
  • Intellia Therapeutics (NTLA +$2.77 after Tuesday’s +$0.24 and Monday’s +$1.94);
  • Fate Therapeutics (FATE +$2.48 after Tuesday’s -$0.33 and Monday’s +$3.80),
  • Editas Medicine (EDIT +$2.28 after Tuesday’s -$0.38 and Monday’s +$2.07);
  • Alnylam Pharmaceuticals (ALNY +$2.14 after Tuesday’s +$1.26 and Monday’s+$6.32),
  • Global Blood Therapeutics (GBT +$1.96 after Tuesday’s +$0.02 and Monday’s +$4.79);
  • bluebird bio (BLUE +$1.66);
  • Sage Therapeutics (SAGE +$1.42 after Tuesday’s +3.97);
  • Ionis Pharmaceuticals (IONS +$1.12 after Tuesday’s -$2.28);

Wednesday’s (7 of 7) decliner:

  • Solid Bioscience (SLDB -$0.27 after Tuesday’s -$0.38);
  • uniQure NV (QURE -$0.14);
  • MiMedx (OTC Pink sheets: MDXG -$0.11);
  • BioLife Solutions (BLFS -$0.09 after Tuesday’s +$0.46);
  • Biostage (BSTG -$0.09);
  • Mesoblast (MESO -$0.02 after Tuesday’s -$0.69);
  • Athersys (ATHX -$0.01);

Closing flat –2 – ReNeuron (RENE.L) and Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Wednesday’s percentage (%) of the 26-upside were +0.54% (CLBS) to +13.18% (NTLA) while the 9-downside ranges from -0.31% (BLFS) to -6.18% (SLDB);
  • Tuesday’s percentage (%) of the 11-upside were +0.03% (GBT) to +6.60% (SAGE) while the 23-downside of -0.07% (BLUE) to -8% (SLDB);
  • Monday’s percentage (%) of the 33-upside were +0.52% (RENE.L) to +13.64% (SLDB) while the 1-downside of -0.30% (MDXG);

 

Sentiment and a few daily indicators:

Market sentiment also got a boost after Eli Lilly said it was looking for FDA clearance for its coronavirus antibody drug. Eli Lilly (LLY) shares jumped 3.4%.

Infection cases <Million>:

  • Wednesday 7.5 M cases
  • Tuesday 7.45 M cases
  • Monday 7.44 M cases

Wednesday’s death rate totaled 210,918 after Tuesday’s 210,195, Monday’s 210.013, Friday’s 207,818, Thursday’s 206,036 and last Wednesday’s 206,036 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Wednesday: 8 out of the 26-upside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 11-upside had higher than the 3-month average volume;
  • Monday: 12 out of the 33-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -1.42 points or -4.82% at 28.06
  • Tuesday was up +0.10 points or +0.36% at 28.06
  • Monday was up +0.33 points or +1.19% at 27.96

Downside volume:

  • Wednesday: 0 out of the 9-downside had higher than the 3-month average volume;
  • Tuesday: 4 out of the 23-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

October, the first month <October> of Q4 …

Wednesday closed positive with 26 advancers, 9 decliners and 2 flats 

Tuesday closed negative with 11 advancers, 23 decliners and 1 flat 

Monday (10/5) closed positive with 33 advancers, 1 decliner and 1 flat 

Friday closed negative with 8 advancers, 26 decliners and 1 flat 

Thursday (10/1) closed negative with 21 advancers, 12 decliners and 2 flats

 

The Bottom Line: As I stated yesterday, profit now, a market storm is brewing.

Pre-open indications are right again … it’s getting to be a constant!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.